Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-09-12

Clinical Trial Update: PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge [Phase 3]

View source ↗

Summary

Phase 3 trial of PH94B nasal spray for social anxiety disorder completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PH94B Nasal Spray (PH94B)

Snippet

Sponsor: VistaGen Therapeutics, Inc. | Conditions: Social Anxiety Disorder | Phase 3 | Status: COMPLETED | Results posted: 2025-09-12